We are live on ! Find out more
MSGR

Direxion mRNA ETF
MSGR

Delisted

MSGR was delisted on the 21st of April, 2023.

Back to rankings

1 hedge funds and large institutions have $323K invested in Direxion mRNA ETF in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less funds holding

Funds holding: 3 → 1 (-2)

69% less capital invested

Capital invested by funds: $1.03M → $323K (-$703K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$363K
2
Bank of America
Bank of America
North Carolina
-$339K
3
Citigroup
Citigroup
New York
-$17.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
1
Citigroup
New York
$323K -$17.3K -1,236 -5%
UBS Group
2
UBS Group
Switzerland
– -$363K -26,810 Closed
Bank of America
3
Bank of America
North Carolina
– -$339K -25,000 Closed

MSGR Hedge Fund Activity: Q4 2022 in Review

1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q4 2022, worth a combined $323K — down 69% from $1.03M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MSGR and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was UBS Group, exiting entirely with an estimated $363K sold.

  • 1 institutional investor held Direxion mRNA ETF (MSGR) as of Q4 2022, down from 3 in Q3 2022.
  • Funds reported $323K of Direxion mRNA ETF stock for Q4 2022, down 69% quarter-over-quarter.
  • 0 funds opened new Direxion mRNA ETF positions in Q4 2022 and 2 closed out, a net change of -2 holders.
  • The largest Direxion mRNA ETF seller in Q4 2022 was UBS Group, an estimated $363K sold.

Based on aggregated 13F filings for Q4 2022.